Novo Nordisk says semaglutide cut obesity rates in young children in trial
Novo said 40.4% of children taking semaglutide were no longer classified as having obesity after 68 weeks, with safety consistent with earlier trials.
10 Articles
10 Articles
Novo Nordisk says semaglutide cut obesity rates in young children in trial
Novo Nordisk's anti-obesity drug, Wegovy, resulted in a weight loss of 40 percent of children between the ages of 6 and 12 in a clinical trial that meant they were no longer considered obese by the end of treatment, Bloomberg reports.
Wegovy, a drug for the treatment of the obesity of the pharmacist Novo Nordisk, helped two in five young children to lose weight enough to stop being classified as obese in a new study. Today, the drug is approved only from the age of 12. 'I feel as if I were 39': At 101, a woman surprised by the routine while working, driving and dancing 'They move there in Barrettos and see my intestine here in RO on a screen', says retired submitted to the 1s…
Worldwide, the number of obese children is increasing. Novo Nordisk now provides first study data on the effects of semaglutide in childhood.
Novo Nordisk STEP Young phase 3 data: 40.4% of children living with obesity achieved a BMI below the obesity threshold with semaglutide and lifestyle modification
STEP Young data show 40.4% of children treated with semaglutide and lifestyle modification were no longer classified as having obesity....
The Danish pharmaceutical company Novo Nordisk announces that the phase 3 Step Young study met its primary endpoint when children aged 6 to under 12 years who received weekly semaglutide together with lifestyle changes had a greater reduction in BMI than the placebo group.
Coverage Details
Bias Distribution
- 57% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
